| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.18 | 0.0004 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.0005 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.0005 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0005 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.0006 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.1 | 0.0009 |
| mRNA | GW-405833 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0009 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |